Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: FDA and EMA Special Drug Designations to Ignite R&D Progress
27 janv. 2023 04h58 HE
|
Research and Markets
Dublin, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of...
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
19 janv. 2023 08h45 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
17 janv. 2023 04h00 HE
|
AKAMPION
- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
03 janv. 2023 07h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Cancer Immunotherapy Global Market Report 2022: Spike in R&D Efforts for the Creation of Novel Oncology Treatment Bolsters 7.5% Annual Growth
29 déc. 2022 06h13 HE
|
Research and Markets
Dublin, Dec. 29, 2022 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market by Product, Distribution Channel, Application, End Use, and by Region - Global Forecast to 2022-2033" report has been added...
Cadherin 17 Target Analysis Report 2022: Opportunity for Drug Discovery and Development as the Landscape is Very Favorable for New Entrants Evan as the 1st Molecules have Entered Clinical Development
16 déc. 2022 04h28 HE
|
Research and Markets
Dublin, Dec. 16, 2022 (GLOBE NEWSWIRE) -- The "Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering. CDH17...
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
15 déc. 2022 07h48 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Worldwide Immuno-oncology Industry to 2028 - Featuring Novartis, Merck, Regeneron Pharmaceuticals and Pfizer Among Others
16 nov. 2022 04h18 HE
|
Research and Markets
Dublin, Nov. 16, 2022 (GLOBE NEWSWIRE) -- The "Immuno-oncology Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's...
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro
15 nov. 2022 04h00 HE
|
AKAMPION
- Promising data presented at Protein and Antibody Engineering Summit (PEGS) - Multi-functional agent targeting three immune checkpoint receptors - Potential as mono- and combination therapy for...
T-Cell Therapy Market Size to Hit $21+ Billion with Booming CAGR Value of 20.7% by 2028 | The Insight Partners
20 oct. 2022 09h22 HE
|
The Insight Partners
New York, Oct. 20, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "T-cell Therapy Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact and...